Anti-GFP antibody was from Roche, Mannheim, Germany, and anti-Grx antibody was from Santa Cruz Biotechnology, Santa Cruz, CA, USA
Proton irradiation significantly reduces crypt viability, mucosal surface area, and cellular proliferation
The forward-looking statements contained in this communication are made only as of March 18, 2026
Cardiovascular outcomes trials such as LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide) have shown that certain GLP-1 receptor agonists significantly reduce major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors
Arizona IV Medics: A Trusted Provider in Phoenix When it comes to receiving vitamin B12 shots, choosing a reputable provider is essential